A recombinant glycoprotein vaccine for herpes simplex type 2: Safety and efficacy

Annals of Internal Medicine

Volumn 122, Issue 12, 1995, Pages 889-898

  Langenberg, Andria G M ^b   Burke, Rae Lyn ^b   Adair, Suzanne F ^b   Sekulovich, Rose ^b   Tigges, Michael ^b   Dekker, Cornelia L ^b   Corey, Lawrence ^a,c  

^a Chiron Biocine's Vacc Res Program ^*

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0029000226     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-122-12-199506150-00001     Document Type: Article

References (51)

1. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19-36.
2. Chapel T, Brown WJ, Jeffries C, Stewart JA. The microbiological flora of penile ulcerations. J Infect Dis. 1978;137:50-6.
3. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med. 1983; 98:973-83.
4. Lavery HA, Connolly JH, Russell JD. Incidence of herpes genitalis in Northern Ireland in 1973-83 and herpes simplex types 1 and 2 isolated in 1982-4. Genitourin Med. 1986;62:24-7.
5. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med. 1989;321: 7-12.
6. Forsgren M. Genital herpes simplex virus infection and incidence of neonatal disease in Sweden. Scan J Infect Dis Suppl. 1990; 60:37-41.
7. Koutsky LA, Ashley RL, Holmes KK, Stevens CE, Critchlow CW, Kiviat N, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Trans Dis. 1990; 176:90-4.
8. Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis. 1990;162:299-305.
9. Christenson B, Bottiger M, Svensson A, Jeansson S. A 15-year surveillance study of antibodies to herpes simplex virus types 1 and 2 in a cohort of young girls. J Infect. 1992;25:147-54.
10. Gibson JJ, Hornung CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis. 1990;162:306-12.
11. Corey L. Genital herpes. In: Holmes KK, ed. Sexually Transmitted Diseases. 2d ed. New York: McGraw-Hill; 1989: 391-413.
12. Schmidt OW, Fife KH, Corey L. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis. 1984;149:645-6.
13. Buchman TG, Roizman B, Nahmias AJ. Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis. 1979;140:295-304.
14. Lakeman AD, Nahmias AJ, Whitley RJ. Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis. 1986;13:61-6.
15. Maitland NJ, Smith IW, Peutherer JF, Robertson DH, Jones KW. Restriction endonuclease analysis of DNA from genital isolates of herpes simplex virus type 2. Infect Immun. 1982;38:834-42.
16. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324:1247-52.
17. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin A. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infection. N Engl J Med. 1987;316:240-4.
18. Koutsky LA, Stevens CE, Holmes KK, Ashley RL, Kiviat NB, Critchlow CW, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med. 1992;326:1533-9.
19. Frenkel LM, Garratty E, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med. 1993;118:414-8.
20. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med. 1981;305:315-9.
21. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98:958-72.
22. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116: 197-202.
23. Johnson RM, Spear PG. Herpes simplex virus glycoprotein D mediates interference with herpes simplex virus infection. J Virol. 1989;63: 819-27.
24. Cohen GH, Dietzschold B, Ponce de Leon M, Long D, Golub E, Varrichio A, et al. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates production of neutralizing antibody. J Virol. 1984;49:102-8.
25. Muggeridge MI, Robert SR, Isola VJ, Cohen GH, Eisenberg RJ. Herpes simplex virus glycoproteins. In: von Regenmortel MH, Neurath AR, eds. Immunochemistry of Viruses: The Basis for Serodiagnosis and Vaccines. New York: Elsevier; 1990:459-81.
26. Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins protect mice against acute virus-induced neurological disease. Infect Immun. 1981;34:192-9.
27. Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex type 2. Infect Immun. 1983;37:1132-7.
28. Stuve LL, Brown-Shimer S, Pachl C, Najarian R, Dina D, Burke RL, The structure and expression of herpes simplex virus type 2 glycoprotein gB2 gene. J Virol. 1987;61:326-35.
29. Laskey LA, Dowbenko D, Simonsin CC, Berman DW. Protection of mice from lethal herpes simplex virus infection by vaccination with a secreted form of cloned glycoprotien gD. Biotechnology. 1984(Jun); 527-32.
30. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis. 1987;155:914-20.
31. Stanberry LR, Myers MG, Stephanopolous DE, Burke RL. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy. J Gen Virol. 1989;70:3177-85.
32. Berman PW, Vogt PE, Gregory T, Lasky LA, Kern ER. Efficacy of recombinant glycoprotein Dsubunit vaccines on the development of primary, recurrent, and latent genital infection with herpes simplex type 2 in guinea pigs. J Infect Dis. 1988;157:897-902.
33. Burke RL. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. J Infect Dis. 1991; 13(Suppl 11):S906-11.
34. Burke RL. Current developments in herpes simplex virus vaccines. Seminars in Virology. 1993;4:187-97.
35. Sanchez-Pescador L, Burke RL, Ott G, Van Nest G. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol. 1988;141:1720-7.
36. Stanberry LR, Burke RL, Meyers MG. Herpes simplex virus glycoprotein treatment of recurrent genital disease. J Infect Dis. 1988;157: 156-63.
37. Ho RJ, Burke RL, Merigan TC. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex genitalis in guinea pigs. J Virol. 1989;63:2951-8.
38. Ashley R, Cent A, Maggs V, Nahmias A, Corey L. Inability of enzyme immunoassays to discriminate between infectons with herpes simplex virus types 1 and 2. Ann Intern Med. 1991;115:520-6.
39. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex type 2 for immunotherapy of genital herpes. Lancet. 1994;343:1460-3.
40. Straus SE, Savarese B, Tigges M, Freifeld AG, Krause PR, Margolis DM, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis. 1993;167:1045-52.
41. Stanberry LR, Harrison CJ, Bernstein DI, Burke RL, Shukla R, Ott G, et al. Herpes simplex glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res. 1989;11:203-14.
42. Duff R, Rapp F. Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nature New Biol. 1973;233: 48-50.
43. Lefkovits I, Waldmann H. Limiting dilution analysis of cells in the immune system: I. The clonal basis of the immune response. Immunology Today. 1984;5:265-8.
44. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981;126: 1614-9.
45. Geysen HM, Rodda SJ, Mason TJ, Tribbick G, Schoofs PG. Strategies for epitope analysis using peptide synthesis. J Immunol Methods. 1987;102:259-74.
46. Reece JC, Geysen HM, Rodda SJ. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol. 1994;151: 6175-84.
47. Reece JC, McGregor DL, Geysen HM, Rodda SJ. Scanning for T helper epitopes with human PBMCs using pools of short synthetic peptides. J Immunol Methods. 1994;172:241-54.
48. Lehmann EL. Theory of Point Estimation. New York: J Wiley; 1983: 106-8.
49. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: J Wiley; 1986.
50. Kohl S, West MS, Prober CG, Sullender WM, Loo LS, Arvin AM. Neonatal antibody-dependent cellular cytotoxicity antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis. 1989;160:770-6.
51. Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, Jones CC, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990;161:653-60.